Privium Fund Management B.V. Sells 61,486 Shares of uniQure N.V. $QURE

Privium Fund Management B.V. lowered its stake in uniQure N.V. (NASDAQ:QURE) by 13.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 386,000 shares of the biotechnology company’s stock after selling 61,486 shares during the period. uniQure accounts for 4.1% of Privium Fund Management B.V.’s portfolio, making the stock its 8th largest position. Privium Fund Management B.V.’s holdings in uniQure were worth $22,531,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently modified their holdings of QURE. Private Trust Co. NA bought a new position in uniQure in the third quarter valued at approximately $28,000. Tower Research Capital LLC TRC grew its stake in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the period. KLP Kapitalforvaltning AS acquired a new position in uniQure in the second quarter valued at about $117,000. Teacher Retirement System of Texas acquired a new position in uniQure in the second quarter valued at about $151,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in uniQure during the second quarter worth about $215,000. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Down 4.0%

NASDAQ:QURE opened at $22.72 on Friday. uniQure N.V. has a 52-week low of $7.76 and a 52-week high of $71.50. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The stock has a 50-day simple moving average of $23.63 and a 200 day simple moving average of $28.33. The company has a market cap of $1.42 billion, a PE ratio of -5.18 and a beta of 0.68.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. On average, sell-side analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Analyst Ratings Changes

QURE has been the topic of a number of analyst reports. Wells Fargo & Company cut their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. Chardan Capital reissued a “buy” rating and set a $53.00 price target on shares of uniQure in a research report on Thursday, December 4th. Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Barclays began coverage on uniQure in a report on Tuesday. They set an “equal weight” rating and a $31.00 target price on the stock. Finally, Royal Bank Of Canada lowered their price target on uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.33.

Insider Activity

In other uniQure news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 102,247 shares of company stock valued at $2,839,298 over the last quarter. 4.79% of the stock is currently owned by company insiders.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.